66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction

Key Takeaways Explain This Topic AI

Polycystic Ovary Syndrome (PCOS) diagnosis requires ≥2 of 3 Rotterdam criteria: 1) oligo- or anovulation (<9 cycles/year or cycle length <21 or >35 days), 2) clinical and/or biochemical hyperandrogenism (modified Ferriman-Gallwey score ≥8, total/free testosterone elevation), and 3) polycystic ovarian morphology on transvaginal ultrasound (≥20 follicles per ovary or ovarian volume ≥10 mL).

Secondary causes of hyperandrogenism and anovulation must be excluded prior to confirming PCOS: serum TSH (hypothyroidism/hyperthyroidism), prolactin (hyperprolactinemia), early-morning 17-hydroxyprogesterone (non-classic 21-hydroxylase deficiency CAH), and 24-hour urinary free cortisol (Cushing syndrome).

First-line ovulation induction for infertile women with PCOS seeking pregnancy is letrozole (aromatase inhibitor 2.5–7.5 mg daily on cycle days 3–7), which demonstrates superior live-birth and ovulation rates compared to clomiphene citrate per the landmark PPCOS II trial.

Infertility evaluation begins after 12 months of regular unprotected intercourse in women <35 years, or after 6 months in women ≥35 years; initial evaluation systematically pairs semen analysis (evaluating male factor in 40–50% of couples) with mid-luteal day 21 serum progesterone (ovulatory status) and hysterosalpingography (tubal patency and uterine cavity).

Phosphodiesterase-5 (PDE-5) inhibitors are first-line for male erectile dysfunction, an early vascular sentinel for occult coronary artery disease; PDE-5 inhibitors are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide) due to life-threatening synergistic cyclic GMP-mediated refractory hypotension.

Last updated: September 2026

Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) represents the most prevalent endocrine-metabolic disorder of reproductive-aged women, affecting 6% to 15% of the population worldwide. It is the leading etiology of anovulatory infertility and is intimately linked to chronic insulin resistance, metabolic syndrome, and significant oncologic risks.

Rotterdam Consensus Diagnostic Criteria

The international Rotterdam criteria (2003, reaffirmed in international consensus guidelines) establish a diagnosis of PCOS when a patient meets at least 2 of the following 3 features , provided other mimicking etiologies have been systematically excluded:

Ovulatory Dysfunction (Oligo- or Anovulation) :

Manifests as cycle intervals > 35 >35 > 35 days (oligomenorrhea) or < 21 <21 < 21 days (polymenorrhea), or < 9 <9 < 9 spontaneous menstrual cycles per calendar year.

Complete cessation of menses for ≥ 3 \ge 3 ≥ 3 consecutive months (secondary amenorrhea).

Clinical Pearl : Some women with PCOS present with seemingly regular 28-to-30-day bleeding that represents anovulatory estrogen-breakthrough bleeding rather than true progesterone-withdrawal menses.

Hyperandrogenism (Clinical and/or Biochemical) :

Clinical Hyperandrogenism : Characterized by hirsutism, evaluated objectively using the modified Ferriman-Gallwey (mFG) scoring system (quantifying terminal hair density across 9 androgen-sensitive body areas; a score ≥ 8 \ge 8 ≥ 8 in Caucasian/Black women or ≥ 4 − 6 \ge 4-6 ≥ 4 − 6 in Asian women confirms clinical hirsutism). Other clinical hallmarks include severe, cystic, treatment-refractory inflammatory acne and androgenic alopecia (terminal hair miniaturization with frontal/parietal vertex thinning).

Biochemical Hyperandrogenism : Elevated serum total testosterone and/or calculated free testosterone (free androgen index). Dehydroepiandrosterone sulfate (DHEA-S) is elevated in approximately 20–30% of patients, indicating adrenal androgen contribution.

Polycystic Ovarian Morphology (PCOM) on Ultrasound :

High-resolution transvaginal ultrasound (TVUS) criteria (per 2018/2023 international guidelines using high-frequency transducers ≥ 8 \ge 8 ≥ 8 MHz): presence of ≥ 20 \ge 20 ≥ 20 follicles measuring 2 to 9 mm in diameter ("string-of-pearls" peripheral follicular arrest) in either ovary , AND/OR an increased ovarian volume ≥ 10 mL \ge 10\text{ mL} ≥ 10 mL (in the absence of a dominant follicle > 10 mm >10\text{ mm} > 10 mm or corpus luteum).

TVUS is avoided or performed transabdominally in virginal adolescents; PCOM on imaging is non-specific in the first 8 years post-menarche and should not be used as a primary diagnostic criterion in adolescents. ROTTERDAM CONSENSUS DIAGNOSIS OF PCOS

Must meet AT LEAST 2 of the following 3 criteria (after excluding mimics):

════════════════════════════════════════════════════════════════════════════════════
1. Oligo- or Anovulation • Menstrual cycle length > 35 days or < 21 days
Fewer than 9 menstrual cycles per year
Secondary amenorrhea ≥ 90 days
────────────────────────────────────────────────────────────────────────────────────
2. Hyperandrogenism • Clinical: Modified Ferriman-Gallwey score ≥ 8,
severe recalcitrant acne, androgenic alopecia
Biochemical: Elevated total or calculated free testosterone
────────────────────────────────────────────────────────────────────────────────────
3. Polycystic Ovarian • Transvaginal ultrasound showing ≥ 20 follicles
Morphology (PCOM) (2–9 mm diameter) in either ovary, OR
Ovarian volume ≥ 10 mL in either ovary
════════════════════════════════════════════════════════════════════════════════════
Systematic Exclusion of Secondary Mimicking Disorders

PCOS remains a diagnosis of exclusion. To avoid catastrophic diagnostic misattribution, family physicians must order the following baseline laboratory panel:

Serum Thyroid-Stimulating Hormone (TSH) : Excludes overt hypothyroidism (elevated TRH stimulates prolactin release and alters gonadotropin pulsatility) or hyperthyroidism.

Serum Prolactin : Excludes prolactinoma/hyperprolactinemia (causes galactorrhea, hypogonadotropic anovulation, and amenorrhea).

Early-Morning Follicular 17-Hydroxyprogesterone (17-OHP) : Drawn at 8:00 AM. Excludes Non-Classic Congenital Adrenal Hyperplasia (NCCAH) caused by mild 21-hydroxylase deficiency. A baseline fasting 17-OHP < 200 ng/dL <200\text{ ng/dL} < 200 ng/dL ( < 6 nmol/L <6\text{ nmol/L} < 6 nmol/L ) reliably rules out NCCAH. Values between 200 − 1000 ng/dL 200-1000\text{ ng/dL} 200 − 1000 ng/dL mandate an ACTH (cosyntropin) stimulation test.

24-Hour Urinary Free Cortisol or Overnight 1-mg Dexamethasone Suppression Test : Indicated when clinical features suggest Cushing Syndrome (moon facies, dorsocervical fat pad, violaceous wide striae > 1 cm >1\text{ cm} > 1 cm , proximal muscle weakness, spontaneous ecchymoses).

Serum Total Testosterone and DHEA-S Elevation Thresholds : Marked, rapid-onset virilization (clitoromegaly, voice deepening, rapid male-pattern balding) with total testosterone > 200 ng/dL >200\text{ ng/dL} > 200 ng/dL or DHEA-S > 700 − 800 mcg/dL >700-800\text{ mcg/dL} > 700 − 800 mcg/dL indicates an androgen-secreting ovarian (Sertoli-Leydig cell tumor) or adrenal neoplasm requiring pelvic TVUS and adrenal multiphasic CT/MRI.

Neuroendocrine & Metabolic Pathophysiology

The core pathophysiologic defect in PCOS is a complex vicious cycle involving the hypothalamic-pituitary-ovarian axis and peripheral carbohydrate metabolism:

Accelerated GnRH Pulsatility : Abnormally rapid hypothalamic gonadotropin-releasing hormone (GnRH) pulse frequency preferentially drives pituitary transcription of luteinizing hormone (LH) over follicle-stimulating hormone (FSH). The resulting high LH:FSH ratio ( > 2 : 1 >2:1 > 2 : 1 or 3 : 1 3:1 3 : 1 ) delivers excessive LH stimulation to ovarian theca cells.

Theca Cell Hyperplasia & Androgen Excess : In response to LH, ovarian theca cells dramatically upregulate cytochrome P450c17alpha (17alpha-hydroxylase/17,20-lyase), hyper-secreting androstenedione and testosterone. Relative FSH deficiency impairs granulosa cell aromatase (CYP19A1), preventing conversion of androgens into estrogens, leading to follicular arrest at the 2–9 mm pre-antral stage.

Insulin Resistance & Compensatory Hyperinsulinemia : Independent of BMI (though markedly exacerbated by central adiposity), 70–80% of women with PCOS exhibit post-receptor insulin signaling defects in skeletal muscle and adipose tissue. Compensatory hyperinsulinemia acts as a co-gonadotropin:

Directly binds ovarian theca cell insulin and IGF-1 receptors to amplify LH-stimulated androgen production.

Suppresses Hepatic Sex Hormone-Binding Globulin (SHBG) : Lower SHBG synthesis markedly increases the percentage of biologically active free testosterone , worsening peripheral virilization.

Endometrial Hyperplasia & Carcinoma Risk : Chronic anovulation leads to continuous, unopposed estrogen exposure without cyclical progesterone-mediated differentiation and withdrawal shedding. This chronic mitogenic stimulus yields a 3- to 5-fold increased lifetime risk of endometrial hyperplasia and type 1 endometrial adenocarcinoma . LONG-TERM METABOLIC COMORBIDITIES OF PCOS

Comorbidity Mechanism & Screening Protocol (ABFM Guideline)
════════════════════════════════════════════════════════════════════════════════════

Dysglycemia / Type 2 • Hyperinsulinemia and peripheral insulin resistance.

Diabetes Mellitus • Mandatory: 2-hour 75-gram Oral Glucose Tolerance Test

(OGTT) at baseline; repeat every 1–3 years.

• Fasting glucose and HbA1c ALONE miss > 50% of impaired

glucose tolerance in PCOS.

────────────────────────────────────────────────────────────────────────────────────
Metabolic Syndrome & • Hypertriglyceridemia, low HDL (< 50 mg/dL), central waist

Cardiovascular Disease circumference > 35 inches (88 cm), elevated BP ≥ 130/85.

• Complete fasting lipid profile at diagnosis.

────────────────────────────────────────────────────────────────────────────────────

Metabolic Dysfunction- • Driven by visceral adiposity, hyperinsulinemia, and lipolysis.

Associated Steatotic Liver • Baseline liver biochemistries (ALT/AST); calculate FIB-4

Disease (MASLD / NAFLD) score; perform hepatic ultrasound if transaminases elevated.

────────────────────────────────────────────────────────────────────────────────────
Obstructive Sleep • Independent of BMI; driven by upper airway collapsibility

Apnea (OSA) induced by hyperandrogenism and visceral fat.

• Formal screening with STOP-BANG questionnaire;

polysomnography if symptomatic.

────────────────────────────────────────────────────────────────────────────────────

Endometrial Hyperplasia • Chronic unopposed estrogen mitogenesis lacking progesterone.

and Adenocarcinoma • Mandatory endometrial biopsy if abnormal uterine bleeding,

amenorrhea > 3–6 months, or endometrial thickness > 7–10 mm.

════════════════════════════════════════════════════════════════════════════════════
Evidence-Based Management of PCOS
1. Foundational Lifestyle Modification

Weight Reduction : A modest 5% to 10% total body weight reduction through caloric restriction (500–750 kcal/day deficit) and regular exercise (≥150 min/week moderate physical activity) reduces visceral adiposity, drops circulating fasting insulin, increases hepatic SHBG by up to 100%, lowers free testosterone, and spontaneously restores regular ovulatory cycles and natural conception in nearly 50% of overweight/obese women.

2. Pharmacotherapy for Patients NOT Desiring Immediate Pregnancy

Combined Oral Contraceptives (COCs) — First-Line :

Mechanisms of Benefit : Suppress pituitary LH secretion (halting theca androgen production); deliver steady synthetic progestin to induce secretory transformation and endometrial atrophy (eliminating endometrial cancer risk); stimulate hepatic SHBG synthesis, reducing free circulating testosterone by 50%.

Formulation Selection : Use low-dose ethinyl estradiol (20–30 mcg) paired with a neutral or anti-androgenic progestin (e.g., drospirenone, desogestrel, norgestimate). Avoid high-androgenic progestins (e.g., levonorgestrel) if hirsutism is severe.

Clinical Pearl : Minimum duration of COC therapy required to observe clinical improvement in hirsutism is 6 months , due to the prolonged growth cycle of terminal hair follicles (anagen phase).

Anti-Androgen Therapy — Spironolactone :

Dosing & Indication : Spironolactone 50 to 100 mg orally twice daily is added as second-line adjuvant therapy if moderate-to-severe hirsutism or androgenic alopecia persists after 6 months of optimized COC therapy.

Mechanism : Competitive antagonist at androgen receptors in the pilosebaceous unit; weak inhibitor of 17alpha-hydroxylase and 5alpha-reductase.

Mandatory Safety Rule : Spironolactone is a potent teratogen capable of causing feminization of a male fetus (hypospadias, cryptorchidism, ambiguous genitalia). It MUST ALWAYS BE CO-PRESCRIBED WITH RELIABLE CONTRACEPTION (typically a COC or intrauterine device). Monitor serum potassium and renal function for hyperkalemia.

Insulin Sensitizers — Metformin :

Dosing & Clinical Role : Metformin 500 to 1000 mg twice daily (or 1500–2000 mg extended-release daily). Improves insulin sensitivity, reduces progression from prediabetes to overt T2D, and promotes mild weight reduction. However, metformin is inferior to COCs for hirsutism and cycle regulation, and inferior to letrozole for ovulation induction. Its primary primary-care indication is for glucose intolerance/prediabetes or as an adjunct when COCs are contraindicated.

3. Management for Patients DESIRING Pregnancy (Ovulation Induction)

Letrozole (Aromatase Inhibitor) — FIRST-LINE GOLD STANDARD :

Dosing Protocol : Administer 2.5 mg orally once daily for 5 days , initiated on cycle day 3, 4, or 5 following spontaneous or progestin-induced withdrawal menses. If ovulation does not occur, titrate stepwise to 5.0 mg daily, then up to a maximum of 7.5 mg daily in subsequent cycles.

Mechanism : Competitively inhibits peripheral aromatase, blocking the conversion of androgens to estrogens. The acute decrease in circulating estradiol removes negative feedback at the hypothalamus and pituitary, triggering a physiologic surge in FSH secretion that drives normal follicle maturation.

Evidence Base (PPCOS II Trial) : The landmark NIH Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) randomized trial demonstrated that letrozole is significantly superior to clomiphene citrate in PCOS, achieving a significantly higher cumulative live birth rate (27.5% vs. 19.1%) , higher ovulation rates, shorter time to pregnancy, and lower rates of multiple gestations (monofollicular ovulation).

Clomiphene Citrate — Second-Line Ovulation Induction :

Dosing : 50 mg daily for 5 days starting on cycle day 3–5, titratable to 100–150 mg daily.

Mechanism : Selective Estrogen Receptor Modulator (SERM) that binds hypothalamic estrogen receptors, blocking negative feedback and increasing gonadotropin release. However, peripheral anti-estrogenic effects on the cervix (hostile, thick cervical mucus) and endometrium (thin, non-receptive lining) contribute to lower live-birth efficacy compared to letrozole.

Exogenous Gonadotropins & Ovarian Drilling : Reserved for letrozole-resistant anovulation under reproductive endocrinology care.

Infertility Evaluation in Primary Care
Clinical Definition & Timing of Workup

Infertility is defined by the American Society for Reproductive Medicine (ASRM) as the failure to achieve a successful pregnancy after 12 months or more of regular, unprotected sexual intercourse .

Age-Based Triggers for Earlier Evaluation :

Women ≥ 35 \ge 35 ≥ 35 years : Initiate comprehensive diagnostic evaluation after 6 months of unsuccessful intercourse due to the accelerated, irreversible physiological decline in oocyte quantity and quality (diminished ovarian reserve).

Women ≥ 40 \ge 40 ≥ 40 years or with Known Risk Factors : Immediate evaluation is warranted without waiting (e.g., oligomenorrhea/amenorrhea, stage III/IV endometriosis, known bilateral tubal occlusion, history of pelvic inflammatory disease, prior pelvic surgery, or known male factor).

Systematic Three-Pronged Diagnostic Approach

Infertility is a couple-based disorder. Etiologies are distributed as: male factor (40–50%) , female ovulatory dysfunction (25–30%) , tubal/pelvic pathology (20–30%) , and unexplained infertility (10–15%). Initial testing must occur in parallel across all three physiological domains: SYSTEMATIC INFERTILITY DIAGNOSTIC WORKUP

Factor Under Evaluation Diagnostic Modality Normal Reference Values / Interpretation

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Male Factor Semen Analysis (WHO 2021 Criteria) • Ejaculate volume: ≥ 1.4–1.5 mL
(Mandatory First Step) • Collected after 2–7 days of abstinence • Sperm concentration: ≥ 15–16 million/mL
Repeat in 4–12 weeks if abnormal • Total motility: ≥ 40–42% (or ≥ 30% progressive)
Normal morphology (Kruger strict): ≥ 4%
───────────────────────────────────────────────────────────────────────────────────────────────────────────
2. Ovulatory Factor A. Mid-Luteal Day 21 Progesterone • Serum progesterone > 3 ng/mL confirms ovulation

(Drawn 7 days prior to menses) (levels > 10 ng/mL reflect robust luteal function).

B. Home Urinary LH Ovulation Kits • Detects pre-ovulatory LH surge (positive 24–36h

prior to follicle rupture).

C. Ovarian Reserve Screening • Day 3 FSH and estradiol, Anti-Müllerian Hormone

(AMH < 1.0 ng/mL suggests diminished reserve).

───────────────────────────────────────────────────────────────────────────────────────────────────────────
3. Tubal & Pelvic Factor Hysterosalpingography (HSG) or • HSG: Fluoroscopic radiopaque dye confirms bilateral

Hysterosalpingo-contrast sonography tubal spillage into peritoneum & normal cavity.

• Saline Infusion Sonohysterography (SIS): High

resolution for polyps, submucosal fibroids, adhesions.

Male Factor Evaluation : Semen analysis is non-invasive, cost-effective, and should be ordered at the very first visit. If the initial semen analysis is abnormal, a confirmatory second semen analysis must be repeated 4 to 12 weeks later to account for standard biological variability across spermatogenic cycles (~74 days).

Ovulatory Factor Evaluation : Mid-luteal serum progesterone is timed precisely to 7 days before anticipated menses (e.g., day 21 of an idealized 28-day cycle, or day 28 of a 35-day cycle). A value > 3 ng/dL >3\text{ ng/dL} > 3 ng/dL confirms luteinization and ovulation.

Tubal & Cavitary Factor Evaluation : Hysterosalpingography (HSG) is performed during the early follicular phase (cycle days 6 to 10, after menstrual bleeding ceases but prior to ovulation) to exclude pregnancy and thin the endometrial lining for optimal visualization. It documents bilateral tubal patency via free peritoneal contrast spillage and reveals intracavitary lesions (endometrial polyps, submucosal leiomyomas, intrauterine synechiae [Asherman syndrome], or congenital Müllerian anomalies).

Female Sexual Dysfunction

Female sexual disorders are classified in the DSM-5 into distinct clinical syndromes requiring significant personal distress lasting ≥ 6 \ge 6 ≥ 6 months:

Female Sexual Interest/Arousal Disorder (FSIAD) / Hypoactive Sexual Desire Disorder (HSDD) :

Absence or marked reduction in sexual interest, erotic thoughts/fantasies, initiation of sexual encounters, and responsiveness to cues.

Etiologies : Psychosocial distress, relationship conflict, depression, selective serotonin reuptake inhibitors (SSRIs; 40–60% incidence of sexual dysfunction), oral contraceptives (high SHBG reducing free testosterone), hyperprolactinemia, and thyroid dysfunction.

Management : Psychosexual counseling, sensate focus exercises. Pharmacotherapy includes Flibanserin (100 mg PO at bedtime; 5-HT1A agonist / 5-HT2A antagonist; boxed warning for severe hypotension and syncope when combined with alcohol, CYP3A4 inhibitors, or severe hepatic impairment) and Bremelanotide (1.75 mg subcutaneous PRN 45 min prior to sexual activity; melanocortin receptor agonist; causes transient BP elevation and nausea).

Female Orgasmic Disorder : Marked delay, infrequency, or absence of orgasm despite adequate arousal and stimulation. Frequently SSRI-induced; management includes dose reduction, switching to bupropion or vortioxetine , or adding sildenafil.

Genitourinary Syndrome of Menopause (GSM) : Formerly termed atrophic vaginitis; causes severe dyspareunia, entry tearing, and secondary avoidance of intercourse (see Section 66.2).

Male Erectile Dysfunction (ED)
Clinical Definition & Etiologic Classification

Erectile dysfunction is defined as the consistent or recurrent inability to achieve or maintain a penile erection of sufficient rigidity to permit satisfactory sexual intercourse for ≥ 3 \ge 3 ≥ 3 months.

Vascular Etiology (Most Prevalent; >70%) : Atherosclerotic endothelial dysfunction of the penile cavernosal arteries (diameter 1–2 mm).

The Artery Size Hypothesis : Because the cavernosal arteries are smaller than coronary (3–4 mm) and carotid arteries, cavernosal endothelial dysfunction manifests clinically 2 to 5 years prior to acute coronary syndromes or stroke . Erectile dysfunction is an established, independent early clinical harbinger of occult coronary artery disease (CAD) .

Mandatory Clinical Action : Any middle-aged male presenting with new-onset vascular ED mandates a formal cardiovascular risk assessment: blood pressure, fasting lipid panel, fasting blood glucose/HbA1c, smoking status, and calculation of the 10-year ASCVD risk score.

Neurogenic Etiology : Peripheral neuropathy (diabetic autonomic neuropathy), spinal cord trauma, pelvic surgical trauma (radical prostatectomy damaging cavernous neurovascular bundles), multiple sclerosis.

Endocrine Etiology : Primary or secondary hypogonadism (morning total testosterone < 300 ng/dL <300\text{ ng/dL} < 300 ng/dL confirmed on two separate 8:00 AM fasting draws), hyperprolactinemia, thyroid disease.

Psychogenic Etiology : Sudden onset, situational (occurs with partner but intact nocturnal or early-morning spontaneous erections), associated with performance anxiety, relationship discord, or acute psychosocial stress.

Medication-Induced ED : Antihypertensives (particularly non-selective beta-blockers [propranolol] and thiazide diuretics), psychotropics (SSRIs, SNRIs, tricyclic antidepressants, antipsychotics), anti-androgens (spironolactone, finasteride, dutasteride, GnRH agonists), and substance misuse (heavy ethanol, opioids). DIAGNOSTIC & PHARMACOTHERAPEUTIC MATRIX FOR ED

Agent / Class Onset & Half-Life (t1/2) Dosing Pearls & Key Considerations

Sildenafil • Onset: 30–60 minutes • Initial dose: 50 mg PO PRN 1 hour before intercourse

(Viagra) • Duration: 4–6 hours (titrate 25–100 mg).

• t1/2: ~4 hours • Must be taken on an EMPTY STOMACH (high-fat meals

delay absorption by > 60 minutes).

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Tadalafil • Onset: 30–45 minutes • Dosing options:

(Cialis) • Duration: Up to 36 hours - PRN: 10–20 mg PO 30–60 min before activity.

("The Weekend Pill") - Daily: 2.5–5.0 mg PO once daily (FDA-approved

t1/2: ~17.5 hours for concurrent BPH and lower urinary tract symptoms).
Food does not affect absorption.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Vardenafil • Onset: 30–60 minutes • Dosing: 10–20 mg PO PRN.

(Levitra) • Duration: 4–5 hours • Fatty meals delay absorption; causes mild QTc prolongation.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Avanafil • Rapid Onset: 15–30 minutes • Dosing: 100–200 mg PO PRN 15–30 min prior to sex.

(Stendra) • Duration: > 6 hours • High selectivity for PDE-5; lowest visual disturbance rate.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Mechanism of Action & Adverse Effect Profile of PDE-5 Inhibitors

During sexual stimulation, non-adrenergic non-cholinergic (NANC) cavernous nerves and endothelial cells release nitric oxide (NO), activating soluble guanylyl cyclase and generating cyclic guanosine monophosphate (cGMP). cGMP induces intracellular calcium efflux and smooth muscle relaxation in the corpora cavernosa, allowing arterial engorgement and veno-occlusion. PDE-5 inhibitors competitively block the phosphodiesterase type 5 enzyme that degrades cGMP, sustaining intracavernosal cGMP and promoting rigid erection. PDE-5 inhibitors require intact sexual desire and stimulation to be effective .

Adverse Effects : Facial flushing (10–15%), headache (10–16%), nasal congestion, dyspepsia/GERD (relaxation of lower esophageal sphincter), low back/myalgia (PDE-11 cross-inhibition with tadalafil), and transient cyanopsia ("blue-tinted vision" due to PDE-6 inhibition in retinal photoreceptors with sildenafil).

Rare Emergencies : Non-arteritic anterior ischemic optic neuropathy (NAION; sudden painless monocular vision loss) and priapism (painful, persistent erection lasting > 4 >4 > 4 hours, requiring urgent cavernosal phenylephrine aspiration to prevent permanent cavernosal fibrosis and impotence).

[!CRITICAL] Strict Nitrate Contraindication Concomitant use of any PDE-5 inhibitor with organic nitrates (e.g., sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) or guanylate cyclase stimulators (e.g., riociguat) is ABSOLUTELY CONTRAINDICATED . Nitrates stimulate cGMP production while PDE-5 inhibitors block cGMP breakdown; this synergistic accumulation of cGMP triggers profound, life-threatening, refractory vasodilation, cardiogenic shock, and fatal myocardial infarction.

Mandatory Safe Washout Periods Prior to Nitrate Administration :

At least 24 hours after the last dose of sildenafil , vardenafil , or avanafil .

At least 48 hours after the last dose of tadalafil (due to its prolonged 17.5-hour half-life).

If a patient develops acute chest pain after taking a PDE-5 inhibitor, organic nitrates must be withheld, and alternative anti-ischemic therapies (beta-blockers, supplemental oxygen, morphine, unfractionated heparin, urgent catheterization) administered.